It looks like you're new here. If you want to get involved, click one of these buttons!
I’ll save folks a few thousand words of reading. The ”sea change” comes at the very end of Mark’s memo:Is he talking about his Sea Change memo?
Whatever pay increase the Times eventually agrees to, the NewsGuild is calling for a cost-of-living adjustment (COLA) that would equal inflation, that would hold Guild members harmless against any increase in inflation. The Times has rejected that COLA proposal even though enlightened employers often agree to cost-of-living adjustments. Not only do such provisions protect employees from having their pay eroded by higher-than-expected inflation, but if inflation remains low, COLA provisions would help the employer’s bottom line by holding down any promised raises. I hope that Times management will see the light on this—and take the enlightened approach.
It’s not as if the Times can’t afford to give newsroom employees a 22.7 percent raise over four years. That’s around ten percentage points above what the Times is offering, and with each percentage point translating into $1.5 million a year in raises, that would cost the Times $15 million annually. That represents just 10 percent of the $150 million stock buyback and a small fraction of the Times’ current $465 million in cash on hand.
Meanwhile, the Times raised paper subscription rates 10% at the start of 2022, and will raise them another 12% at the start of 2023. That's more, cumulative, in just two years than the workers are asking for spread over a period of four years.In the current negotiations, the NewsGuild is demanding a wage increase averaging 5.25 percent a year over four years.... According to the union, the Times’ latest wage offer comes to 2.875 per year...
The Primecap funds have certainly endured a few years of bad luck -- POAGX in particular was perfectly positioned to crater when covid struck as it had outsized stakes in things like airlines and cruise lines. Yet the fund is idiosyncratic, that's for sure. All three of the funds have seen significant redemptions, resulting in large capital gains distributions for several years (worsening tax-adjusted performance). Anyone considering a new investment should take a look at the portfolio and be comfortable with the huge chunk of biotech and pharmaceuticals in there. It's almost a healthcare fund.
© 2015 Mutual Fund Observer. All rights reserved.
© 2015 Mutual Fund Observer. All rights reserved. Powered by Vanilla